CIBC Bancorp USA
ALLO icon

CIBC Bancorp USA’s Allogene Therapeutics ALLO Stock Holding History

CIBC Bancorp USA’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$42K Buy
26,239
+11,586
+79% +$22K ﹤0.01% 2186
2026
Q2 		$30.5K Buy
+14,653
New +$32.2K ﹤0.01% 1908
2025
Q3 		$20K Buy
+16,163
New +$19.3K ﹤0.01% 1454

Other funds holding ALLO

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Pfizer
Pfizer New York $164M AUM 53.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $161B AUM 86.05% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

CIBC Bancorp USA's ALLO Position: Q3 2026 in Review

CIBC Bancorp USA increased its Allogene Therapeutics (ALLO) stake by 79% in Q3 2026, buying an estimated $22K and bringing the position to 26,239 shares worth $42K. The position accounts for ﹤0.01% of the portfolio, ranked #2186.

CIBC Bancorp USA first reported a position in ALLO in Q3 2025 and has held it in 3 quarters since. 141 funds tracked by Wall St. Rank hold ALLO as of Q3 2026.

  • CIBC Bancorp USA held 26,239 shares of Allogene Therapeutics worth $42K as of Q3 2026.
  • CIBC Bancorp USA bought 11,586 Allogene Therapeutics shares in Q3 2026, an estimated $22K.
  • Allogene Therapeutics made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q3 2026, its #2186 holding.
  • CIBC Bancorp USA first reported a position in Allogene Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 141 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2026.

Based on CIBC Bancorp USA's 13F filing for Q3 2026, filed 13 Nov 2026.